MedDataX Logo

Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers

NCT ID: NCT01091753

Last Updated: 2010-10-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of nocturnal administration of Anti-hypertensive medications in Non-dippers.

Efficacy variables.

1. ECHO
2. 24hr. horter
3. IMT
4. BUN/crea, urine analysis (microalbulinuria
5. Cardio vascular event. "

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

morning administration group

Group Type PLACEBO_COMPARATOR

Valsaltan, amlodipine

Intervention Type DRUG

nti hypertensive medication time (nocturnal administration vs morning administration

nocturnal administration group

Group Type EXPERIMENTAL

Valsaltan, amlodipine

Intervention Type DRUG

nti hypertensive medication time (nocturnal administration vs morning administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valsaltan, amlodipine

nti hypertensive medication time (nocturnal administration vs morning administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Essential hypertension (stage 1-2)
2. 24hr. holer : non-dipper
3. Age 18 \~70.

Exclusion Criteria

1. Any known malignant disease
2. Renal failure , creatinine \>2.0mg/dl
3. Liver disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yonsei University, College of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dong hun Choi

Role: PRINCIPAL_INVESTIGATOR

professor of division of Cardiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Severance Hospital, Yonsei University College of Medicine

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2007-0440

Identifier Type: -

Identifier Source: org_study_id